Protection efficacy induced by nanoliposomal soluble antigens as a
vaccine candidate against Toxoplasma gondii RH strain in BALB/c Mice
Abstract
An effective vaccine against Toxoplasma gondii is an ideal strategy for
controlling acute or chronic toxoplasmosis. In order to boost immune
reactions to various antigens, liposomes may be utilized as
immunoadjuvants. We encapsulated soluble Toxoplasma antigen (SA) and
imiquimod adjuvant in 1, 2-Dioleoyl-3-trimethylammonium Propane (DOTAP)
liposomes to evaluate the immune response induced by this vaccine. Three
times with 2-week intervals, BALB/C mice were immunized subcutaneously
with different formulations. The type of generated immune reaction, as
well as the protection extent, was assessed through the percent survival
survey of BALB/c mice after challenge with Toxoplasma gondii, the
evaluation immune reaction with the generation of cytokine (IFN-γ,
IL-4), and titration of IgG isotypes. Less mortality was observed in the
immunized mice by liposome DOTAP + imiquimod + SA that was meaningfully
different (P<0.01) in comparison to other groups. The IgG2a
and IFN-γ secretion highest levels were seen with liposome DOTAP +
imiquimod + SA more than the control group (P<0.001) and
(P<0.0001), respectively. The results of this research reveal
that a cellular immune reaction is produced by the formulation of
liposome DOTAP + imiquimod + SA, which is protective facing T. gondii
challenge